Role of AMPK-SREBP Signaling in Regulating Fatty Acid Binding-4 (FABP4) Expression following Ethanol Metabolism

Simple Summary Liver damage is a common occurrence following sustained, heavy alcohol consumption. One of the earliest pathologies associated with alcohol-dependent liver disease is increased hepatic fat accumulation. In healthy individuals, fatty acid binding protein-1 plays an important role in transporting lipids in hepatocytes. However, in alcohol-dependent liver disease, fatty acid binding protein-4 (a protein normally expressed in fat storing cells and white blood cells) is produced by hepatocytes and can stimulate liver cancer growth. In this study, we report that alcohol metabolism via cytochrome P450 2E1 drives increased fatty acid binding protein-4 production and fat accumulation. These data suggest that increased fatty acid binding protein-4 production may promote tumor growth in cancer cells in alcohol-dependent liver disease. Abstract Fatty acid binding protein-4 (FABP4) is not normally expressed in the liver but is induced in alcohol-dependent liver disease (ALD)). This study sought to identify mechanisms whereby ethanol (EtOH) metabolism alters triglyceride accumulation and FABP4 production. Human hepatoma cells which were stably transfected to express alcohol dehydrogenase (ADH) or cytochrome P4502E1 (CYP2E1) were exposed to EtOH in the absence/presence of inhibitors of ADH (4-methylpyrazole) or CYP2E1 (chlormethiazole). Cells were analyzed for free fatty acid (FFA) content and FABP4 mRNA, then culture medium assayed for FABP4 levels. Cell lysates were analyzed for AMP-activated protein kinase-α (AMPKα), Acetyl-CoA carboxylase (ACC), sterol regulatory element binding protein-1c (SREBP-1c), and Lipin-1β activity and localization in the absence/presence of EtOH and pharmacological inhibitors. CYP2E1-EtOH metabolism led to increased FABP4 mRNA/protein expression and FFA accumulation. Analysis of signaling pathway activity revealed decreased AMPKα activation and increased nuclear-SREBP-1c localization following CYP2E1-EtOH metabolism. The role of AMPKα-SREBP-1c in regulating CYP2E1-EtOH-dependent FFA accumulation and increased FABP4 was confirmed using pharmacological inhibitors and over-expression of AMPKα. Inhibition of ACC or Lipin-1β failed to prevent FFA accumulation or changes in FABP4 mRNA expression or protein secretion. These data suggest that CYP2E1-EtOH metabolism inhibits AMPKα phosphorylation to stimulate FFA accumulation and FABP4 protein secretion via an SREBP-1c dependent mechanism.

[1]  I. McKillop,et al.  Cytochrome P450 2E1 dependent hepatic ethanol metabolism induces fatty acid binding protein 4 and steatosis. , 2022, Alcoholism: Clinical and Experimental Research.

[2]  S. Chakravarthi,et al.  Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy , 2021, Toxicology reports.

[3]  A. Eguchi,et al.  The Role of Elevated Liver-Type Fatty Acid-Binding Proteins in Liver Diseases , 2021, Pharmaceutical Research.

[4]  I. McKillop,et al.  Fatty acid binding protein-4 promotes alcohol-dependent hepatosteatosis and hepatocellular carcinoma progression , 2020, Translational oncology.

[5]  H. Seitz.  The role of cytochrome P4502E1 in the pathogenesis of alcoholic liver disease and carcinogenesis. , 2019, Chemico-biological interactions.

[6]  I. McKillop,et al.  Role of fatty acid binding proteins (FABPs) in cancer development and progression. , 2019, Cellular signalling.

[7]  G. Arteel,et al.  Effect of ethanol on lipid metabolism. , 2019, Journal of hepatology.

[8]  Jian Li,et al.  Upstream stimulating factor 1 suppresses autophagy and hepatic lipid droplet catabolism by activating mTOR , 2018, FEBS letters.

[9]  R. G. Austin,et al.  Altered fatty acid‐binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[10]  D. Xie,et al.  FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma , 2018, Cancer medicine.

[11]  H. Uehara,et al.  Adipose tissue:Critical contributor to the development of prostate cancer. , 2018, The journal of medical investigation : JMI.

[12]  C. Deng,et al.  Emerging roles of SIRT1 in fatty liver diseases , 2017, International journal of biological sciences.

[13]  J. Girona,et al.  Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. , 2017, The Journal of endocrinology.

[14]  I. McKillop,et al.  Role of alcohol in the development and progression of hepatocellular carcinoma. , 2016, Hepatic oncology.

[15]  Min You,et al.  Sirtuin 1 signaling and alcoholic fatty liver disease. , 2015, Hepatobiliary surgery and nutrition.

[16]  K. Izumi,et al.  Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression , 2014, International journal of cancer.

[17]  R. Bataller,et al.  Alcoholic and non-alcoholic steatohepatitis. , 2014, Experimental and molecular pathology.

[18]  E. Ravussin,et al.  Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes , 2014, Journal of medicinal chemistry.

[19]  T. Zeng,et al.  Inhibition of cytochrome P4502E1 by chlormethiazole attenuated acute ethanol-induced fatty liver. , 2014, Chemico-biological interactions.

[20]  B. Bay,et al.  β-Adrenergic Agonist and Antagonist Regulation of Autophagy in HepG2 Cells, Primary Mouse Hepatocytes, and Mouse Liver , 2014, PloS one.

[21]  T. Zeng,et al.  CMZ Reversed Chronic Ethanol-Induced Disturbance of PPAR-α Possibly by Suppressing Oxidative Stress and PGC-1α Acetylation, and Activating the MAPK and GSK3β Pathway , 2014, PloS one.

[22]  N. Plant,et al.  Fatty acid binding proteins: tissue-specific functions in health and disease , 2014, Current opinion in clinical nutrition and metabolic care.

[23]  Xiangyan Li,et al.  Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling , 2014, Molecular Cancer Therapeutics.

[24]  Daniel P Feldmann,et al.  Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms , 2013, Oncotarget.

[25]  M. Assfalg,et al.  Ligand Binding Promiscuity of Human Liver Fatty Acid Binding Protein: Structural and Dynamic Insights from an Interaction Study with Glycocholate and Oleate , 2013, Chembiochem : a European journal of chemical biology.

[26]  J. Verrax,et al.  Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease. , 2013, Biochemical pharmacology.

[27]  R. Ahima,et al.  Temporal effects of ethanol consumption on energy homeostasis, hepatic steatosis, and insulin sensitivity in mice. , 2013, Alcoholism, clinical and experimental research.

[28]  Karuna Rasineni,et al.  Molecular mechanism of alcoholic fatty liver , 2012, Indian journal of pharmacology.

[29]  Min You,et al.  Regulation of hepatic lipin‐1 by ethanol: Role of AMP‐activated protein kinase/sterol regulatory element‐binding protein 1 signaling in mice , 2012, Hepatology.

[30]  A. Cederbaum.  Alcohol Metabolism , 2020, Encyclopedia of Gastroenterology.

[31]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[32]  Mengwei Zang,et al.  AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. , 2011, Cell metabolism.

[33]  Lin Lu,et al.  Receptor Mediated Elevation in FABP4 Levels by Advanced Glycation End Products Induces Cholesterol and Triacylglycerol Accumulation in THP-1 Macrophages , 2011, Lipids.

[34]  A. McIntosh,et al.  Hepatic phenotype of liver fatty acid binding protein gene-ablated mice. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[35]  S. Weinman,et al.  Proteasome activation by hepatitis C core protein is reversed by ethanol-induced oxidative stress. , 2008, Gastroenterology.

[36]  R. Gillilan,et al.  Structural basis for activation of fatty acid-binding protein 4. , 2007, Journal of molecular biology.

[37]  D. Crabb,et al.  Alcohol and lipid metabolism , 2006, Journal of gastroenterology and hepatology.

[38]  N. Osna,et al.  Recombinant Hep G2 cells that express alcohol dehydrogenase and cytochrome P450 2E1 as a model of ethanol-elicited cytotoxicity. , 2006, The international journal of biochemistry & cell biology.

[39]  D. Crabb,et al.  Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[40]  P. Bedossa,et al.  Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.

[41]  A. Cederbaum,et al.  Adenovirus-mediated Overexpression of Catalase in the Cytosolic or Mitochondrial Compartment Protects against Cytochrome P450 2E1-dependent Toxicity in HepG2 Cells* , 2001, The Journal of Biological Chemistry.

[42]  D Tabor,et al.  Regulation of gene expression by SREBP and SCAP. , 2000, Biochimica et biophysica acta.

[43]  M. Brown,et al.  A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  X. Hua,et al.  SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis , 1994, Cell.

[45]  F. Schroeder,et al.  Selective binding of cholesterol by recombinant fatty acid binding proteins. , 1991, The Journal of biological chemistry.